Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00465270 · ClinicalTrials.gov registry record · NA
Patent Foramen Ovale Closure or Medical Therapy After Stroke - RESPECT Trial
A NA study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 980
- Enrollment target
NCT00465270 is a NA study that has completed, run by Abbott Medical Devices. The registered enrollment target is 980 participants.
The verdict
NCT00465270, a NA study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 980 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate whether percutaneous Patent Foramen Ovale (PFO) closure, using the AMPLATZER PFO Occluder, is superior to current standard of care medical treatment in the prevention of recurrent embolic stroke.
Interventions
- DEVICE AMPLATZER PFO Occluder
- OTHER Standard of Care - Medical Management
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 980 participants |
| Start Date | 2003-08 |
| Est. Completion | 2016-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00465270
The ClinicalTrials.gov registry entry for NCT00465270 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 980 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AMPLATZER PFO Occluder is the first listed.
NCT00465270 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00465270 about?
NCT00465270 is a clinical study titled "Patent Foramen Ovale Closure or Medical Therapy After Stroke - RESPECT Trial". The purpose of this study is to investigate whether percutaneous Patent Foramen Ovale (PFO) closure, using the AMPLATZER PFO Occluder, is superior to current standard of care medical treatment in the prevention of recurrent embolic stroke.
What is the current status of trial NCT00465270?
This trial is currently completed. It is a NA study. The enrollment target is 980 participants. The study started on 2003-08. Estimated completion is 2016-05.
What interventions are being tested in trial NCT00465270?
The interventions under investigation include: AMPLATZER PFO Occluder (DEVICE), Standard of Care - Medical Management (OTHER).
Who is sponsoring clinical trial NCT00465270?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.